Skip to main content

Table 1 Baseline characteristics of all included participants

From: Competing risk of the specific mortality among Asian-American patients with prostate cancer: a surveillance, epidemiology, and end results analysis

Variables Total (n = 26,293) Ethnic Chinese (n = 4928) Other Asian-Americans (n = 21,365)
Year of diagnosis, year, n (%)    
 2004 2265 (8.61) 426 (8.64) 1839 (8.61)
 2005 2128 (8.09) 426 (8.64) 1702 (7.97)
 2006 2279 (8.67) 469 (9.52) 1810 (8.47)
 2007 2524 (9.60) 517 (10.49) 2007 (9.39)
 2008 2303 (8.76) 477 (9.68) 1826 (8.55)
 2009 2364 (8.99) 448 (9.09) 1916 (8.97)
 2010 2278 (8.66) 430 (8.73) 1848 (8.65)
 2011 2367 (9.00) 412 (8.36) 1955 (9.15)
 2012 1979 (7.53) 374 (7.59) 1605 (7.51)
 2013 1913 (7.28) 302 (6.13) 1611 (7.54)
 2014 1854 (7.05) 307 (6.23) 1547 (7.24)
 2015 2039 (7.75) 340 (6.90) 1699 (7.95)
Age at diagnosis, years, n (%)    
 < 65 10,484 (39.87) 1737 (35.25) 8747 (40.94)
 ≥ 65 15,809 (60.13) 3191 (64.75) 12,618 (59.06)
Marital status, n (%)    
 Married 19,750 (75.12) 3826 (77.64) 15,924 (74.53)
 Unmarried, single or widowed 6543 (24.88) 1102 (22.36) 5441 (25.47)
Histological types, n (%)    
 Adenocarcinoma 25,964 (98.75) 4838 (98.17) 21,126 (98.88)
 Squamous-cell carcinoma, mucinous carcinoma or sarcoma 329 (1.25) 90 (1.83) 239 (1.12)
Grade, n (%)    
 I 11,817 (44.94) 2193 (44.50) 9624 (45.05)
 II 14,476 (55.06) 2735 (55.50) 11,741 (54.95)
T Stage, n (%)    
 T1 10,817 (41.14) 2212 (44.89) 8605 (40.28)
 T2 12,257 (46.62) 2187 (44.38) 10,070 (47.13)
 T3 2736 (10.41) 449 (9.11) 2287 (10.70)
 T4 483 (1.84) 80 (1.62) 403 (1.89)
N Stage, n (%)    
 N0 25,650 (97.55) 4824 (97.89) 20,826 (97.48)
 N1 643 (2.45) 104 (2.11) 539 (2.52)
M Stage, n (%)    
 M0 25,476 (96.89) 4785 (97.10) 20,691 (96.85)
 M1 817 (3.11) 143 (2.90) 674 (3.15)
Radiotherapy, n (%)    
 No 25,313 (96.27) 4769 (96.77) 20,544 (96.16)
 Yes 980 (3.73) 159 (3.23) 821 (3.84)
Chemotherapy, n (%)    
 No 26,130 (99.38) 4895 (99.33) 21,235 (99.39)
 Yes 163 (0.62) 33 (0.67) 130 (0.61)
Surgery, n (%)    
 No 15,449 (58.76) 3010 (61.08) 12,439 (58.22)
 Yes 10,844 (41.24) 1918 (38.92) 8926 (41.78)
Regional nodes positive, n (%)    
 No 5845 (22.23) 1011 (20.52) 4834 (22.63)
 Yes 20,448 (77.77) 3917 (79.48) 16,531 (77.37)
Follow time (months), M (Q1, Q3) 71 (38, 107) 75 (42, 109) 71 (38, 106)
Outcomes, n (%)    
 Survived at the end of the follow-up period 21,636 (82.29) 4077 (82.73) 17,559 (82.19)
 Died of PCa 1038 (3.95) 171 (3.47) 867 (4.06)
 Died of other causes 3619 (13.76) 680 (13.80) 2939 (13.76)
  1. PCa prostate cancer